The use of GnRH agonists in the long protocol is associated with some disadvantages for the patients, such as a long treatment period, the increased risk of the ovarian hyperstimulation syndrome (OHSS), more recurrent manifestation of side effects during the desensitization period (Orvieto & Patrizio, 2013). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.